Clinical trial

Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer

NCT04138342

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Quantum dots coated with veldoreotide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Topical approved placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-09-15

PhasePHASE1

Conditions

Breast Cancerverified · MONDO: breast cancer

Skin Cancerverified · MONDO: skin cancer

Skin Diseasesunresolved

Interventions

Quantum dots coated with veldoreotideDRUG

Topical approved placeboDRUG

Sponsors & collaborators

Al-Azhar Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04138342 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.